Gallbladder cancer: current status

Bibliography

• GREENLEE RT, MURRAY T, BOLDEN S, WINGO PA: Cancer Statistics. CA Cancer Clin. (2000) 50:7–33.
   PubMed Web of Science ®Google Scholar
• LOTZE MT, FLICKINGER JC, CARR BI: Hepatobiliary neoplasms. In: Cancer: Principles and Practice of Oncology (4th edit). Devita VT, Hellman S, Rosenburg SA, (Eds), JB Lippincott, Philadelphia, USA (1993).
   Google Scholar
• DONOHUE JH, STEWART AK, MENCK HR: The National Cancer data Base report on carcinoma of the gallbladder. Cancer (1998) 15:2618–2628.
   Google Scholar
• SERRA I, CALVO A, SHARP A: Gallbladder cancer. Rev Med Chil (1987) 115: 706–708.
   PubMed Web of Science ®Google Scholar
• ROA I, ARAYA JC, DE ARETXABALA Xet al.: Gallbladder disease in the area of Temuco. Rev Med. ail. (1989) 117:889–894.
   Google Scholar
• NARDI M, D'AMICO G, CASCIANI Eet al.: Cancer of Gallbladder. Minerva ChM (1997) 52:583–587.
   PubMedGoogle Scholar
• KUMAR S, JAIN A, JAIN S: Gallbladder carcinoma: experience of 116 cases. Trop. Castroenteral (2000) 21:65–68.
   PubMedGoogle Scholar
• AHMAD M, KHAN AH, MANSOOR A: The pattern of malignant tumors in northern Pakistan. I Pak. Med. Assoc. (1991) 41:270–273.
   PubMedGoogle Scholar
• LEVIN B: Gallbladder carcinoma. Ann. °pea (1999) 4:S129–S130.
   Google Scholar
• CSENDES A, BECERRA M, ROJAS J, MEDINA E: Number and size of patients with asymptomatic and symptomatic gallstones and gallbladder carcinoma: a prospective study of 592 cases. Castrointest. Surg. (2000) 5:481–485.
   Google Scholar
• ZOU S, ZHANG L: Relative risk factors analysis of 3 922 cases of gallbladder cancer. Zhonghua. Wai. Ke. Zhi. (2000) 11:805–808.
   Google Scholar
• DUTTA U, GARG PK, KUMAR R, TANDON RK: Typoid carriers among patients with gallstones are at an increased risk for carcinoma of the gallbladder. Am. Castmenterol (2000) 3:784–787.
   Google Scholar
• SHUKLA VK, SINGH H, PANDEY M et al.: Carcinoma of the gallbladder-is it a sequel of typhoid. Dig. as. Sci. (2000) 5:900–903.
   Google Scholar
• ROA I, IBACACHE G, CARVALLO J, MELO A: Microbiological study of gallbladder bile in a high risk zone for gallbladder cancer. Rev Med. ChM (1999) 9:1049–1055.
   Google Scholar
• MATSUKURA N, YOKOMURO S, YAMADA S: Association between Helicobacter bilis in bile and biliary tract malignancies: H. bilis in bile from Japanese and Thai patients with benign and malignant disease in the biliary tract. Jpn.j Cancer Res. (2002) 7:842–847.
   Google Scholar
• MOERMAN CJ, BUENO DE MESQUITA HB, RUNIA S: Smoking, alcohol consumption and the risk of cancer of the biliary tract; a population-based case-control study in The Netherlands. Eur.j Cancer Prey (1994) 5:427–436.
   Google Scholar
• SCOTT TE, CARROLL M, COGLIANO FD et al.: A case-control assessment of risk factors for gallbladder carcinoma. Dig. Dis. Sci. (1999) 8:1619–1625.
   Google Scholar
• STROM BL, SOLOWAY RD, RIOS-DALENZ JL: Risk factors for gallbladder cancer. An international collaborative case-control study. Cancer (1995) 7:1515–1517.
   Google Scholar
• MOERMAN CJ, BUENO DE MESQUITA HB, SMEETS FW, RUNIA S: Consumption of foods and micronutrients and the risk of cancer of the biliary tract. Prey. Med. (1995) 6:591–602.
   Google Scholar
• PANDEY M, SHUKLA VK: Diet and gallbladder cancer: a case-control study. Eur.j Cancer Prey (2002) 4:365–368.
   Google Scholar
• ENDOH K, NAKADAIRA H, YAMAZAKI 0: Risk factors for gallbladder cancer in Chilean females. Nippon. Koshu. Eiset Zasshi. (1997) 2:113–122.
   Google Scholar
• GALLUS S, NEGRI E, CHATENOUD L et al.: Post-menapausal hormonal therapy and gallbladder cancer risk. Int. Cancer (2002) 5:762–763.
   Google Scholar
• BUCKLES DC, LINDOR KD, LARUSSO NF et al: In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am. J. Castmenterol (2002) 5:1138–1142.
   Google Scholar
• SHUKLA VK, RASTOGI AN, ADUKIA TK et al.: Organchlorine pesticides in carcinoma of the gallbladder: a case-control study. Ear: J. Cancer Prey (2001) 2:153–156.
   Google Scholar
• NYBERG U, NILSSON B, TRAVIS LB, HOLM LE, HALL P: Cancer incidence among Swedish patients exposed to radioactive thorostrast: a forty-year follow-up survey. Radiat Res. (2002) 4:419–425.
   Google Scholar
• MA Z, WANG Z, ZHANG J: Carcinogenicity of bile from cholecystolithiasis patients. Zhonghua. Vi. Xue. Zhi. (2001) 5:268–270.
   Google Scholar
• MANO H, ROA I, ARAYA JC et al.: Comparison of mutagenic activity of bile between Chilean and Japanese female patients having cholelithiasis. Mutat Res. (1996) 1–2:73–77.
   Google Scholar
• STROM BL, SOLOWAY RD, RIOS-DALENZ J et al.: Biochemical epidemiology of gallbladder cancer. Hepatology (1996) 6:1402–1411.
   Google Scholar
• TAZUMAN S, KAJIYAMA G: Carcinogenesis of malignant lesions of the gall bladder. The impact of chronic inflammation and gallstones. Langenbecks Arch. Surg. (2001) 3:224–229.
   Google Scholar
• RASHID A, GAO YT, BHAKTA S et al: Beta-catenin mutations in biliary tract cancers: a population-based study in China. Cancer Res. (2001) 8:3406–409.
   Google Scholar
• YANAGISAWA N, MIKAMI T, MITOMI H et al.: CD44 variant overexpression in gallbladder carcinoma associated with tumor dedifferentiation. Cancer (2001) 2:408–416.
   Google Scholar
• KIM SW, HER KH, JANG JY et al: K-ras oncogene mutation in cancer and precancerous lesions of the gallbladder. Surg. Oncol (2000) 4:246–251.
   Google Scholar
• MASUHARA S, KASUYA K, AOKI T et al.: Relation between K-ras codon 12 mutation and p53 protein overexpression in gallbladder cancer and biliary ductal epithelia in patients with pancreaticobiliary maljunction.j Hepatobiliary Pancreat Surg. (2000) 2:198–205.
   Google Scholar
• YAMATO T, SASAKI M, WATANABE Y, NAKANUMA Y: Expression of MUCI and MUC2 mucin core proteins and their messenger RNA in gall bladder carcinoma: an immunohistochemical and in situ hybridization study. Pathol (1999) 1:30–37.
   Google Scholar
• KASHIWAGI H, KIJIMA H, DOWAKI S et al.: MUCI and MUC2 expression in human gallbladder carcinoma: a clinicpathological study and relationship with prognosis. Oncol Rep. (2001) 3:485–489.
   Google Scholar
• YOKOYAMA N, HITOMI J, WATANABE H, AJIOKA et al.: Mutations of p53 in gallbladder carcinomas in high-incidence areas of Japan and Chile. Cancer Epidemiol Biomarkers Prey (1998) 4:297–301.
   Google Scholar
• ROA I, MELO A, ROA J et al.: P53 genemutation in gallbladder cancer. Rev Med. ChM (2000) 3:251–258.
   Google Scholar
• YAMAMOTO, S, KITADAI Y, TSUCHIDA A et al: Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human gallbladder lesions. Ear: .1. Cancer (2000) 2:257–263.
   Google Scholar
• HUI AM, LI X, SHI YZ et al.: Cyclin D1 overexpression is a critical event in g allbladder carcinogenesis and independently predicts decreased survival for patients with gallbladder carcinoma. Clin. Cancer Res. (2000) 11:4272–277.
   Google Scholar
• EGUCHI N, FUJII K, TSUCHIDA A et al.: Cyclin E overexpression in human gallbladder carcinomas. Oncol Rep. (1999) 1:93–96.
   Google Scholar
• SHI YZ, HUI AM, LI X et al: Overexpression of retinoblastoma protein predicts decreased survival and correlates with loss of pl6INK4 protein in gallbladder carcinomas. Clin. Cancer Res. (2000) 10:4096–4100.
   Google Scholar
• HUI AM, SHI YZ, LI X et al.: Proliferative marker Ki-67 in gallbladder carcinomas: high expression level predicts early recurrence after surgical resection. Cancer Lett (2002) 2:191–198.
   Google Scholar
• GUSTAFSSON U, EINARRSON C, ERIKSSON LC et al.: DNA ploidy and S-phase fraction in carcinoma of the gallbladder related to histopathology, number of gallstones and survival. Anal. Cell. Pathol (2001) 3–4:143–152.
   Google Scholar
• HANADA K, ITOH M, FUJII K et al: Expression of the proliferative cell nuclear antigen (PCNA) in adenocarcinoma of the gallbladder, and its relationship to prognosis. Scand. j Clin. Lab. Invest.(1995) 5:377–382.
   Google Scholar
• OKITA S, KONDOH S, SHIRAISHI K et al.: Expression of vascular endothelial growth factor correlates with tumor progression in gallbladder cancer. Int. J. amyl (1998) 5:1013–1018.
   Google Scholar
• LI X, HUI AM, SHI YZ et al: Reduced p21 (WAF1/CIP1) expression is an early event in gallbladder carcinogenesis and is of prognostic significance for patients with carcinomas of the gallbladder. Hum. Pathol. (2001) 8:769–770.
   Google Scholar
• HUI AM, LI X, SHI YZ, TORZILLI G et al.: p27 (Kipl) expression in normal epithelia, precancerous lesions, and carcinomas of the gallbladder: association with cancer progression and prognosis. Hepatology (2000) 5:1068–1072.
   Google Scholar
• CAO L, DUCHROW M, WINDHOVEL U et al: Expression of MDR1 mRNA and encoding P-glycoprotein in archival formalin-fixed paraffin-embedded gall bladder cancer tissues. Eur. J. Cancer. (1998) 10:1612–1617.
   Google Scholar
• GROSSMAN EM, LONGO WE, PANESAR N et al.: The role of cyclooxygenase enzymes in the growth of human gall bladder cancer cells. Carcinogenesis (2000) 7:1403–1409.
   Google Scholar
• LEE CS, PIRDAS A: Epidermal growth factor receptor immunoreactivity in gallbladder and extrapepatic biliary tract tumours. Pathol Res. Pract. (1995) 11:1087–1091.
   Google Scholar
• ROA I, ARAYA JC, VILLASECA M et al.:Gallbladder cancer: immunohistochemical expression of the protein related to estrogen receptor (p29) and of the protein induced by estrogen (pS2). Rev Med. Chg. (1995) 11:1333–1340.
   Google Scholar
• MALIK IA, ABBAS Z, SHAMSI Z et al:Immuno-histochemical analysis of estrogen receptors on the malignant gallbladder tissue. J. Pak. Med. Assoc. (1998) 5:123–126.
   Google Scholar
• KO CY, SCHMIT P, CHENG L, THOMPSON JE: Estrogen receptors in gallbladder cancer: detention by and improved immunohistochemical assay. Am. Surg. (1995) 10:930–933.
   Google Scholar
• DE ARETXABA X, RIEDEMAN JP, ROA I et al: CA 19-9 and carcinoembryonic antigen in gallbladder cancer. Rev Med. ChB. (1996)1:11–20.
   Google Scholar
• DOWAKI S, KIJIMA H, KASHIWAGI H et al.: CEA immunmohistochemical localization is correlated with growth and metastasis of human gallbladder carcinoma. Int. J. Oncol (2000) 1:49–53.
   Google Scholar
• WIBBENMEYER LA, SHARAFUDDIN MJ, WOLVERSON MK et al: Sonographic diagnosis of unsuspected gallbladder cancer: imaging findings in comparison with benign gallbladder conditions. Am. J. Roentgenol (1995) 5:1169–1174.
   Google Scholar
• PANDEY M, SOOD BP, SHUKLA RC et al.: Carcinoma of the gallbladder: role of sonography in diagnosis and staging. J. Gin. Ultrasound (2000) 5:227–232.
   Google Scholar
• KIM BS, HA HK, LEE IJ et al: Accuracy of CT in local staging of gallbladder carcinoma. Acta RadioL (2002) 1:71–76.
   Google Scholar
• SCH WARTS LH, BLACK J, FONG Y et al.: Gallbladder carcinoma: findings at MR imaging with MR cholangiopancreatography. I Comput. Assist. Tomogr. (2002) 3:405–410.
   Google Scholar
• MALIK, I: Clinicopathological features and management of gallbladder cancer in Pakistan: a prospective study of 233 cases. J Gastroenterol Hepatol (2003) 18:950–953.
   PubMed Web of Science ®Google Scholar
• ROA I, DE ARETXABALA X, ARAYA JCet al.: Incipient gallbladder carcinoma. Clinical and pathological study and prognosis in 196 cases. Rev Med. ChB. (2001) 10:1113–1120.
   Google Scholar
• PPAIMELAH, KARPPINEN A, H OCKERSTEDT K et al.: Poor prognosis of gallbladder cancer persists regardless of improved diagnostic methods. Incidence and results of surgery during 20 years in Helsinki. Ann. Chir. Gynaecol (1997) 1:13–17.
   Google Scholar
• NORTH JH JR, PACK MS, HONG C, RIVERA DE: Prognostic factors adenocarcinoma of the gallbladder: an analysis of 162 cases. Am. Surg. (1998) 5:437–440.
   Google Scholar
• RIOS ZAMBUDIO A, SANCHEZ BUENO F, GARCIA MARCILLA JA et al.: Prognostic factors in gallbladder cancer. Gastroenterol Hepatol (2001) 6:281–286.
   Google Scholar
• BARTLETT DL, FONG Y, FORTNER JGet al.: Long-term results after resection for gallbladder cancer. Implications for staging and management. Ann. Surg. (1996) 5:639–646.
   Google Scholar
• WEILAND ST, MAHVI DM, NIEDERHUBER JE et al.: Should suspected early gallbladder cancer be treated laparoscopically. Gastrointest. Surg. (2002) 1:50–56.
   Google Scholar
• KONDO S, NIMURA Y, HAYAKAWA N et al.: Regional and para-aortic lymphadenectomy in radical surgery for advanced gallbladder carcinoma. Br. J. Surg. (2000) 87:418–422.
   PubMed Web of Science ®Google Scholar
• FONG Y, JARNAGIN W, BLUMGART LH: Gallbladder cancer: comparison of patients presenting initially for definitive operation with those presenting after prior noncurative intervention. Ann. Surg. (2000) 4:557–569.
   Google Scholar
• NAKAMURA S, SUZUKI K, KONNO H eta].: Outcome of extensive surgery for TNM stage IV carcinoma of the gallbladder. Hepatogastroenterology (1999) 28:2138–2143.
   Google Scholar
• TODOROKI T, TAKAHASHI H, KOIKE N et al.: Outcomes of aggressive treatment of stage IV gallbladder cancer and predictors of survival. Hepatogastroenterology (1999) 28:2114–2121.
   Google Scholar
• SCHAUER RJ, MEYER G, BARETTON Get al.: Prognostic factors and long-term results after surgery for gallbladder carcinoma: a retrospective study of127 patients. Langenbecks Arch. Surg. (2001) 2:110–117.
   Google Scholar
• KONDO S, NIMURA Y, KAMIYA Jet al.:Five-year survivors after aggressive surgery for stage iv gallbladder cancer. Hepatobiliary Pancreat. Sing. (2001) 6:511–517.
   Google Scholar
• DE ARETXABALA X, ROA I, BURGOS L et al.: Preoperative chemoradiotherapy in the treatment of gallbladder cancer. Am. Surg. (1999) 3:241–246.
   Google Scholar
• KRES JJ, SCHILD SE, HENNING GT et al.: Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma. Intl Radiat. OncoL Biol. Phys. (2002) 1:167–175.
   Google Scholar
• TODOROKI T, KAWAMOTO T, OTSUKA M et al.: Benefits of combining radiotherapy with aggressive resection for stage IV gallbladder cancer. Hepatogastroenterology (1999) 27:1585–1591.
   Google Scholar
• PATTY, JONES, D, HOQUE, A et al: Phase II trial of intravenous flouracil and subcutaneous interferon alfa-26 for biliary tract cancer. J Chu. Oncol (1996) 8:2311–2315.
   Google Scholar
• MALIK I, AZIZ Z: Prospective evaluation of efficacy and toxicity of 5-FU and folinic acid (Mayo Clinic Regimen) in patients with advanced cancer of the gallbladder. Am.j Clin. Oncol (2003) 2:124–126.
   Google Scholar
• JONES DV JR, LOZANO R, HOQUE A et al.: Phase II study of pacfitaxel therapy for unresectable bifiary tree carcinomas. Clin. Oncol (1996) 8:2306–2310.
   Google Scholar
• KIM TW, CHANG HM, KANG HJ et al.:Phase II study of capecitabine plus cisplatin as first-fine chemotherapy in advanced bifiary cancer. Ann. Oncol (2003) 14:1115-1120. ao.GALLARDO JO, RUBIO B, FODOR M et al.: A Phase II study of gemcitabine in gallbladder carcinoma. Ann. Oncol (2001) 10:1403–1406.
   Google Scholar
• DOVAL D et al.: Gemcitabine and cisplatin in chemotherapy-naïve, unresectable gallbladder cancer: a large multicenter, Phase II study. Proc. Am. Soc. Clin. Oncol (2001) (Abstract 622).
   Google Scholar
• MALIK I, AZIZ Z, ZAIDI MANZOORSH, SETHURAMAN G: Gemcitabine and cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder. Am..1. Clin. °nail (2003) 2:174–177.
   Google Scholar
• REYES-VIDAL JM, GALLARDO J, YANEZ E et al: Gemcitabine and cisplatin in the treatment of patients with unresectable or metastatic gallbladder cancer: results of the Phase II GOCCHI study 2000–2013. Presented at the Gastrointestinal Cancers Symposium Proceedings (2004) (Abstract 87).
   Google Scholar
• QIAN J, QIN S, HE Z: Arsenic trioxide in the treatment of advanced primary liver and gallbladder cancer. Zhonghua. Zhong. Liu. Za. Zhi. (2001) 6:487–489.
   Google Scholar
• ADJEI AA, ERLICHMAN C: A Phase I trial of MTA and gemcitabine in patients with locally advanced or metastatic cancer. Semin. Oncol (1999) 2(Suppl. e6):94–98.
   Google Scholar
• FIEBIGER WC, SCHEITHAUER W, TRAUB T et al: Absence of therapeutic efficacy of the somatostatin analogue lanreotide in advanced primary hepatic cholangiocellular cancer and adenocarcinoma of the gallbladder despite in vivo somatostatin-receptor expression. Scand. Casteroenterol (2002) 2:222–225.
   Google Scholar
• AICC Cancer Staging Handbook (6th edit). Greene FL, Page DL, Fleming ID et al. (Eds), Springer-Verlag, New York, NY, USA (2002). Affiliation Imtiaz A Malik MD Loma Linda University Medical Center, Division of Hematology-Oncology, 11234 Anderson St, Suite 1531, Loma Linda, CA 92354, USA Tel: +1 909 558 8017; Fax: +1 909 558 0219; E-mail: [email protected]
   Google Scholar